Chapter 013

Antiparkinson Drugs

James T. Boyd, Clayton English, and Karen M. Lounsbury

GENERAL REFERENCES

  1. Connolly BS, Lang AE: Pharmacological treatment of Parkinson disease: a review, JAMA 311(16):1670–1683, 2014. PUBMED Abstract
  2. Cummings J, Isaacson S, Mills R, et al.: Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial, Lancet 383(9916):533–540, 2014. PUBMED Abstract
  3. DiPiro JT, Talbert RL, Yee GC, et al.: Pharmacotherapy: a pathophysiologic approach, 9th ed., New York, 2014, McGraw-Hill Education.
  4. Fahn S, Jankovic J, Hallett M: Principles and practice of movement disorders, 2nd ed., New York, 2011, Elsevier/Saunders.
  5. Fukayo S, Nonaka N, Shimizu T, et al.: Oral health of patients with Parkinson’s disease: factors related to their better dental status, Tohoku J Exp Med 201:171–179, 2003. PUBMED Abstract
  6. Goodman LS, Brunton LL, Chabner B, et al.: Goodman & Gilman’s pharmacological basis of therapeutics, 12th ed., New York, 2011, McGraw-Hill.
  7. Jost WH, Bruck C: Drug interactions in the treatment of Parkinson’s disease, J Neurol 249(Suppl 3):III/24–29, 2002. PUBMED Abstract
  8. Kaakkola S: Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson’s disease, Int Rev Neurobiol 95:207–225, 2010. PUBMED Abstract
  9. Kakkar AK, Dahiya N: Management of Parkinson’s disease: current and future pharmacotherapy, Eur J Pharmacol 750:74–81, 2015. PUBMED Abstract
  10. Lobbezzo F, Naeije M: Dental implications of some common movement disorders: a concise review, Arch Oral Biol 52:395–398, 2007. PUBMED Abstract
  11. Mhyre TR, Boyd JT, Hamill RW, et al.: Parkinson’s disease, Subcell Biochem 65:389–455, 2012. PUBMED Abstract
  12. Ogawa N: Factors affecting levodopa effects in Parkinson’s disease, Acta Med Okayama 54:95–101, 2000. PUBMED Abstract
  13. Olanow CW, Kieburtz K, Odin P, et al.: Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study, Lancet Neurol 13(2):141–149, 2014. PUBMED Abstract
  14. Stacy M: Medical treatment of Parkinson disease, Neurol Clin 27(3):605–631, 2009. PUBMED Abstract
  15. Tomlinson CL, Stowe R, Patel S, et al.: Systematic review of levodopa dose equivalency reporting in Parkinson’s disease, Mov Disord 25(15):2649–2653, 2010. PUBMED Abstract
  16. Verstraeten A, Theuns J, Van Broeckhoven C: Progress in unraveling the genetic etiology of Parkinson disease in a genomic era, Trends Genet 31:140–149, 2015. PUBMED Abstract